Precision Personalized Medicine: Bridging Harvard Hospitals Excellence to the Frontlines
Bridging Elite Medical Networks to Global Clinical Frontlines. Harnessing cutting-edge technology and secure cross-border protocols to connect regional clinics directly with world-class medical leadership.
Direct Access to Harvard Hospitals
Premier Medical Institutions
We bridge geographic divides to align patients, sovereign entities, and clinical leaders for unmatched diagnostic depth, second opinions, and high-stakes healthcare interventions.
Design and implement customized remote access to the world-renowned medical professionals at Boston’s elite Harvard-affiliated hospitals: Massachusetts General Hospital, Brigham Women’s Hospital and Boston Children’s Hospital. We bridge geographic divides to connect patients directly with global leaders in medical excellence.
By uniting premier research networks—including the Harvard Hospitals medical ecosystem—with regional hospitals and specialized clinics worldwide, we bridge the gap between isolated local facilities and global centers of excellence.
Key Pillars of the Telemedicine Ecosystem
01
Global Expert Access
Through secure, real-time diagnostic sharing and high-stakes virtual consultations, local medical professionals gain direct collaboration channels with the world’s leading physicians.
02
Seamless Digital Integration:
Our telemedicine infrastructure operates as a core component of a broader digital governance framework, supporting continuous online medical education, clinical training, and data-driven healthcare administration.
03
Empowering Vulnerable Regions:
By bridging institutional silos, we ensure that advanced healthcare innovations and specialized diagnostics reach developing and underserved communities effectively.
Precision &
Personalized Medicine
Advanced Diagnostic Integration and Custom N-of-1 Discovery.
We design and implement comprehensive Precision & Personalized Medicine programs capable of fusing deep clinical intelligence with genomics, transcriptomics, molecular pathology, pharmacogenomics, and—for complex cases—proteomics, metabolomics, patient-derived cellular models, and advanced functional approaches.
For high-complexity needs, we engineer customized solutions for individual patients via N-of-1 research programsdeveloped alongside leading Harvard scientists and premier hospitals, leveraging rapid deployment through Contract Research Organizations (CROs) across the USA, UK, and Europe. Our advanced protocols utilize patient-derived induced pluripotent stem cells (iPSCs) disease models, precise biomarkers, and multiomic profiling for bespoke therapeutic discovery.
The Precision
& Personalized Medicine Workflow
Once we have successfully modeled a patient’s disease using induced pluripotent stem cells (iPSCs), run comprehensive multiomic sequencing, and mapped the exact dysregulated pathways, we reach the critical pivot point of precision medicine: how to fix the biological system.
At this stage, we possess a high-resolution, patient-specific cellular avatar (the iPSCs) alongside a definitive blueprint of what is broken. The two core therapeutic routes—Pharmacology and Genetic Treatments—target different, highly specific stages of the biological pipeline.
Route 1:
Pharmacological Treatments
(Targeting the Products)
Pharmacology focuses squarely on the downstream consequences of a disease. Instead of rewriting the genetic source, it deploys sophisticated small molecules or biologics to alter the behavior of proteins and metabolites that multiomic analysis has revealed to be misbehaving.
Small Molecule Inhibitors and Activators:
If transcriptomics and proteomics indicate that a specific enzymatic pathway is hyperactive, targeted small molecules are introduced to bind to and block that enzyme.
Targeted Protein Degradation (PROTACs):
When a toxic, disease-driving protein accumulates within the cellular machinery, these specialized molecules tag the rogue protein for destruction by the cell's internal recycling system.
Drug Repurposing Libraries:
High-throughput screening (HTS) is executed directly on the patient's differentiated iPSCs, testing thousands of existing, FDA-approved compounds to discover which ones immediately normalize the dysregulated biological pathway.
Route 2:
Genetic Treatments
(Targeting the Source)
Genetic therapies operate upstream at the root cause. Their objective is to rewrite, erase, or silence errant genetic instructions at the DNA or RNA level before dysregulated proteins can ever be synthesized.
CRISPR/Cas9 and Next-Gen Editors (DNA Level):
If genomics uncovers a precise causative mutation, CRISPR is deployed to cleanly cut and correct the DNA sequence. Advanced variations, such as Base Editors and Prime Editors, enable precise single-nucleotide corrections without fracturing the underlying DNA strands.
Antisense Oligonucleotides (ASOs) and siRNA (RNA Level):
If transcriptomics reveals that a gene is producing a toxic or mutated RNA strand, synthetic ASOs bind directly to that specific RNA. This blocks translation or triggers enzymatic destruction, effectively silencing the gene upstream.
Gene Augmentation:
When a pathology stems from a loss-of-function mutation—where a critical gene is missing or broken—a fully functional copy of the gene is delivered directly into target cells using safe, optimized viral vectors like AAV.
Integrating the Choice Back
Into Your iPSC and Multiomic Workflow
The true elegance of the iPSC and multiomics framework is that it eliminates clinical guesswork. We are not forced to speculate which therapeutic route holds the answer; we can test both simultaneously and rigorously inside the laboratory using the patient's own living, cultured cells:
- Validation via Genetics: We utilize CRISPR to correct the mutation directly within the patient's iPSCs. If repairing the gene fully normalizes the multiomic signature (the proteome and metabolome) of the cells, it definitively confirms that a genetic intervention is a viable strategic pathway.
- Screening via Pharmacology: In parallel, we apply chemical libraries directly to unedited, diseased iPSC-derived cells. Advanced multiomic readouts reveal precisely which compounds successfully steer the dysregulated molecular networks back toward a healthy, resilient baseline state.
The Harvard Hospitals Bridge: Global Telemedicine
Geographical location should never dictate the quality of healthcare a patient receives. Through SMG’s advanced telemedicine ecosystem, regional and developing clinics gain unprecedented access to elite medical networks anchored by Harvard Hospitals. By establishing secure, high-speed diagnostic and consultation bridges, we empower local practitioners to consult directly with world-class medical authorities, review complex cases collaboratively, and bring top-tier global expertise right to the local frontlines—backed by the enduring excellence of Harvard’s Hospitals premier medical institutions.